Intriguingly, a CD26+ circulating tumor cell (CTC) population that is CD44+ and CD66c+ but EpCAM− and CD133− is an independent prognostic factor for CRC recurrence (Lieto et al., 2015). This evidence concerns the gene EPCAM and neoplasm.